REG - Nuformix PLC - Resignation of Auditor

NuformixAnnouncement

05/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221205:nRSE5200Ia&default-theme=true

RNS Number : 5200I  Nuformix PLC  05 December 2022

5 December 2022

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Resignation of Auditor

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces the
resignation of Jeffreys Henry LLP ("Jeffreys Henry") as auditors to the
Company.  Section 519 of the Companies Act 2006 (the "Act") requires Jeffreys
Henry to send a statement of the reasons for ceasing to hold office.  They
have stated that in accordance with Section 519 of the Act, they are ceasing
to hold office due to the following reason:

 

"Jeffreys Henry LLP have resigned as auditor on the grounds that the firm has
taken the decision not to register as an auditor eligible to undertake Public
Interest Entity audits."

 

There are no circumstances connected with Jeffreys Henry ceasing to hold
office as auditor which they consider should be brought to the attention of
the Company's members or creditors.  As required by the Companies Act,
Nuformix will send a copy of the resignation letter to shareholders.

 

The appointment of a new auditor will be announced in due course following the
completion of a tender process.

 

Enquiries:

 

 Nuformix plc
 Dr Julian Gilbert, Non-executive Chairman         Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFLFSTFLLSIIF